U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07832292) titled 'A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer' on Sept. 16.
Brief Summary: The purpose of this study is to evaluate how well JNJ-101556143 works in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced form of prostate cancer that has spread and no longer responds to hormone therapy. The study will measure the overall response (tumor shrinkage or disappearance) following treatment with JNJ-101556143.
Study Start Date: Sept. 28
Study Type: INTERVENTIONAL
Condition:
Prostatic Neoplasms
Intervention:
DRUG: JNJ-101556143
Participants will receive JNJ-10...